Toggle navigation
About
Abstract
Editorial Board
Subscription & Newsletter
Contact
Issues
This issue
19-2
All issues
Download PDF
Download EPUB
Editor's Selection
This issue
19-2
Browse by topic
Browse by contributor
Dialogue & Opinion
Abstracts
Abstracts
Search
Classification List
Abstracted Journals
Index of Authors
News & Reports
Home
Abstracts
Index of Authors
Author #27524
advertisement
Hashimoto M
15
Showing records 1 to 15 |
Display all abstracts from
Hashimoto M
75509
Preperimetric Glaucoma Prospective Observational Study (PPGPS): Design, baseline characteristics, and therapeutic effect of tafluprost in preperimetric glaucoma eye
Aizawa N
PLoS ONE
2017; 12: e0188692
75271
Prediction of Visual Field Progression in Patients with Primary Open-Angle Glaucoma, Mainly Including Normal Tension Glaucoma
Nitta K; Wajima R
Scientific reports
2017; 7: 15048
75509
Preperimetric Glaucoma Prospective Observational Study (PPGPS): Design, baseline characteristics, and therapeutic effect of tafluprost in preperimetric glaucoma eye
Kunikata H; Shiga Y
PLoS ONE
2017; 12: e0188692
75271
Prediction of Visual Field Progression in Patients with Primary Open-Angle Glaucoma, Mainly Including Normal Tension Glaucoma
Tachibana G; Inoue S
Scientific reports
2017; 7: 15048
75509
Preperimetric Glaucoma Prospective Observational Study (PPGPS): Design, baseline characteristics, and therapeutic effect of tafluprost in preperimetric glaucoma eye
Tsuda S; Yokoyama Y
PLoS ONE
2017; 12: e0188692
75271
Prediction of Visual Field Progression in Patients with Primary Open-Angle Glaucoma, Mainly Including Normal Tension Glaucoma
Ohigashi T; Otsuka N
Scientific reports
2017; 7: 15048
75509
Preperimetric Glaucoma Prospective Observational Study (PPGPS): Design, baseline characteristics, and therapeutic effect of tafluprost in preperimetric glaucoma eye
Omodaka K; Yasui T
PLoS ONE
2017; 12: e0188692
75271
Prediction of Visual Field Progression in Patients with Primary Open-Angle Glaucoma, Mainly Including Normal Tension Glaucoma
Kurashima H; Santo K
Scientific reports
2017; 7: 15048
75509
Preperimetric Glaucoma Prospective Observational Study (PPGPS): Design, baseline characteristics, and therapeutic effect of tafluprost in preperimetric glaucoma eye
Kato K
PLoS ONE
2017; 12: e0188692
75271
Prediction of Visual Field Progression in Patients with Primary Open-Angle Glaucoma, Mainly Including Normal Tension Glaucoma
Hashimoto M
Scientific reports
2017; 7: 15048
75509
Preperimetric Glaucoma Prospective Observational Study (PPGPS): Design, baseline characteristics, and therapeutic effect of tafluprost in preperimetric glaucoma eye
Kurashima H; Miyamoto E
PLoS ONE
2017; 12: e0188692
75271
Prediction of Visual Field Progression in Patients with Primary Open-Angle Glaucoma, Mainly Including Normal Tension Glaucoma
Shibahara H
Scientific reports
2017; 7: 15048
75509
Preperimetric Glaucoma Prospective Observational Study (PPGPS): Design, baseline characteristics, and therapeutic effect of tafluprost in preperimetric glaucoma eye
Hashimoto M
PLoS ONE
2017; 12: e0188692
75271
Prediction of Visual Field Progression in Patients with Primary Open-Angle Glaucoma, Mainly Including Normal Tension Glaucoma
Hirukawa M; Sugiyama K
Scientific reports
2017; 7: 15048
75509
Preperimetric Glaucoma Prospective Observational Study (PPGPS): Design, baseline characteristics, and therapeutic effect of tafluprost in preperimetric glaucoma eye
Nakazawa T
PLoS ONE
2017; 12: e0188692
Issue
19-2
Table of Contents
Editor's Selection
PDF
EPUB
Change Issue
26-1
25-4
25-3
25-2
25-1
24-4
24-3
24-1/2
23-4
23-3
23-2
23-1
22-4
22-3
22-2
22-1
21-4
21-3
21-2
21-1
20-4
20-3
20-2
20-1
19-4
19-3
19-2
19-1
18-4
18-3
18-2
18-1
17-4
17-3
17-2
17-1
16-4
16-3
16-2
16-1
15-4
15-3
15-2
15-1
14-4
14-3
14-2
14-1
13-4
13-3
13-2
13-1
12-4
12-3
12-2
12-1
11-4
11-3
11-2
11-1
10-4
10-3
10-2
10-1
9-4
9-3
9-2
9-1
8-4
8-3
8-2
8-1
7-3
7-2
7-1
6-3
6-2
6-1
5-3
5-2
5-1
4-3
4-2
4-1
3-3
3-2
3-1
2-3
2-2
2-1
1-3
1-2
1-1
advertisement
We would like to use Google Analytics to see which parts of the review are read. It is only used to count visits, never for advertising.
Privacy statement
Decline
Accept